Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis

M.P.P. van Herk-Sukel, L.V. van de Poll-Franse, A.C. Voogd, G.A.P. Nieuwenhuijzen, J.W.W. Coebergh, R.M.C. Herings

Research output: Contribution to journalArticleScientificpeer-review

69 Citations (Scopus)
Original languageEnglish
Pages (from-to)843-851
JournalBreast Cancer Research and Treatment
Volume122
Issue number3
Publication statusPublished - 2010

Cite this